In cooperation with


Multigen-assays in breast cancer

Several multigen-assays have been developed in breast cancer to estimate patients? benefit from systemic treatment. In clinical routine, the use of these tests will be limited to women whose tumors fall in a range where the benefit from chemotherapy is uncertain as indicated by histopathological parameters and the test result might determine whether adjuvant chemotherapy followed by endocrine treatment is superior to adjuvant endocrine treatment alone. Up to now, prospective-randomized trials are missing which could proof a benefit from chemotherapy for patients with a high risk of recurrence according to the test results. In this overview, the most common gene tests are introduced. Current literature and the use of these tests in clinical routine are discussed critically.

CME Prakt Fortbild Gynakol Geburtsmed Gynakol Endokrinol 2014; 10(2): 176–187

Breast cancer, prognosis, prediction, multigene assays, biomarker

Isabell Witzel
Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik
für Gynäkologie, Brustzentrum, Hamburg
Reviewer: Anke Kleine-Tebbe, Berlin,
und Susanne Briest, Leipzig

Witzel I. Gentests ... Gynakol Geburtsmed Gynakol Endokrinol 2014; 10(2): 176–187 publiziert 31.07.2014 ©akademos Wissenschaftsverlag 2014 ISSN 1614-8533